A Multi-Center, Open Label, Phase I, Dose Finding and Expansion Study of RO7051790 Administered Orally in Patients With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

Trial Profile

A Multi-Center, Open Label, Phase I, Dose Finding and Expansion Study of RO7051790 Administered Orally in Patients With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs RG 6016 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 20 Jul 2017 According to an Oryzon media release, Roche is planning to finalize this trial in the following months.
    • 08 Jun 2017 Planned End Date changed from 1 Aug 2019 to 23 Sep 2019.
    • 08 Jun 2017 Planned primary completion date changed from 1 Aug 2019 to 23 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top